These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6164250)

  • 1. Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan.
    van Praag HM; de Haan S
    Acta Psychiatr Scand Suppl; 1981; 290():191-201. PubMed ID: 6164250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression vulnerability and 5-hydroxytryptophan prophylaxis.
    van Praag H; de Hann S
    Psychiatry Res; 1980 Sep; 3(1):75-83. PubMed ID: 6160599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of depression with serotonin precursors.
    van Praag HM
    Biol Psychiatry; 1981 Mar; 16(3):291-310. PubMed ID: 6164407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin precursors in the treatment of depression.
    van Praag HM
    Adv Biochem Psychopharmacol; 1982; 34():259-86. PubMed ID: 6753514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Harold E. Himwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders.
    Praag HM
    Biol Psychiatry; 1977 Feb; 12(1):101-31. PubMed ID: 300032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central serotonin metabolism and frequency of depression.
    van Praag HM; de Haan S
    Psychiatry Res; 1979 Dec; 1(3):219-24. PubMed ID: 95233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotoninergic dysfunction in the 47, XYY syndrome.
    Bioulac B; Benezech M; Renaud B; Noel B; Roche D
    Biol Psychiatry; 1980 Dec; 15(6):917-23. PubMed ID: 6161648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remarks on the therapy of depressions with amine precursors.
    Hippius H; Matussek N
    Psychopathology; 1986; 19 Suppl 2():132-5. PubMed ID: 3495015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients.
    Koyama T; Lowy MT; Meltzer HY
    Am J Psychiatry; 1987 Mar; 144(3):334-7. PubMed ID: 2435178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders.
    Bouman TK; Niemantsverdriet-van Kampen JG; Ormel J; Slooff CJ
    J Affect Disord; 1986; 11(3):275-80. PubMed ID: 2951414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In search of the mode of action of antidepressants. 5-HTP/tyrosine mixtures in depressions.
    van Praag HM
    Neuropharmacology; 1983 Mar; 22(3 Spec No):433-40. PubMed ID: 6304561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.
    Kane JM; Quitkin FM; Rifkin A; Ramos-Lorenzi JR; Nayak DD; Howard A
    Arch Gen Psychiatry; 1982 Sep; 39(9):1065-9. PubMed ID: 6810839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological correlations of suicide and aggressivity in major depressions (with melancholia): 5-hydroxyindoleacetic acid and cortisol in cerebral spinal fluid, dexamethasone suppression test and therapeutic response to 5-hydroxytryptophan.
    López-Ibor JJ; Saiz-Ruiz J; Pérez de los Cobos JC
    Neuropsychobiology; 1985; 14(2):67-74. PubMed ID: 2418384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate.
    Meltzer HY; Lowy M; Robertson A; Goodnick P; Perline R
    Arch Gen Psychiatry; 1984 Apr; 41(4):391-7. PubMed ID: 6422900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The indoleamine hypothesis of depression: an overview and pilot study.
    Zarcone VP; Berger PA; Brodie KH; Sack R; Barchas JD
    Dis Nerv Syst; 1977 Aug; 38(8):646-53. PubMed ID: 328245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic indications for serotonin-potentiating compounds: a hypothesis.
    van Praag HM; Kahn R; Asnis GM; Lemus CZ; Brown SL
    Biol Psychiatry; 1987 Feb; 22(2):205-12. PubMed ID: 2434148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT brain function in affective disorder: d,l-fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis.
    Mannel M; Müller-Oerlinghausen B; Czernik A; Sauer H
    J Affect Disord; 1997 Nov; 46(2):101-13. PubMed ID: 9479614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients.
    Kaneko M; Kumashiro H; Takahashi Y; Hoshino Y
    Neuropsychobiology; 1979; 5(4):232-40. PubMed ID: 312470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
    Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
    J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.